Jennifer Bush Biography and Net Worth

Ms. Bush is Chief Operating Officer of Artiva, leading our legal, people and culture, information technology, patient engagement, and community access initiatives. Bringing deep experience in executive leadership and operations, Ms. Bush joined Artiva in 2020 as General Counsel and became our Chief Legal & People Officer in 2021. Prior to joining Artiva, Ms. Bush was Senior Vice President, General Counsel of Organovo, Inc., a tissue engineering company where she led the company’s legal, human resources, regulatory, and government relations functions. Prior to that, Ms. Bush served in a senior legal role at Broadcom. Ms. Bush began her career as a commercial and intellectual property litigator at Fish & Richardson, where she spent 10 years representing companies in the life science, medical device, and software industries. Ms. Bush received her bachelor’s degree in history and Latin American studies from Princeton University and her law degree from Yale Law School. Ms. Bush also serves on the board of directors of the San Diego Association of Corporate Counsel.

What is Jennifer Bush's net worth?: The estimated net worth of Jennifer Bush is at least $3.32 million as of May 19th, 2026. Bush owns 337,920 shares of Artiva Biotherapeutics stock worth more than $3,318,374 as of June 23rd. This net worth estimate does not reflect any other assets that Bush may own. Learn More about Jennifer Bush's net worth.
How do I contact Jennifer Bush?: The corporate mailing address for Bush and other Artiva Biotherapeutics executives is , , . Artiva Biotherapeutics can also be reached via phone at (858) 267-4467 and via email at [email protected]. Learn More on Jennifer Bush's contact information.
Has Jennifer Bush been buying or selling shares of Artiva Biotherapeutics?: In the last ninety days, Jennifer Bush has sold $79,197.90 of Artiva Biotherapeutics stock. Most recently, Jennifer Bush sold 8,790 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a transaction totalling $79,197.90. Following the completion of the sale, the chief operating officer now directly owns 337,920 shares of the company's stock, valued at $3,044,659.20. Learn More on Jennifer Bush's trading history.
Who are Artiva Biotherapeutics' active insiders?: Artiva Biotherapeutics' insider roster includes Fred Aslan (President and Chief Executive Officer), Subhashis Banerjee (Insider), Jennifer Bush (COO), Christopher Horan (Insider), and Heather Raymon (SVP). Learn More on Artiva Biotherapeutics' active insiders.
Are insiders buying or selling shares of Artiva Biotherapeutics?: In the last year, Artiva Biotherapeutics insiders bought shares 9 times. They purchased a total of 9,501,755 shares worth more than $103,750,036.39. In the last year, insiders at the sold shares 9 times. They sold a total of 113,602 shares worth more than $741,174.90. The most recent insider tranaction occured on June, 16th when Director Ra Capital Management, L.P. bought 124,893 shares worth more than $1,110,298.77. Insiders at Artiva Biotherapeutics own 21.4% of the company. Learn More about insider trades at Artiva Biotherapeutics.
Information on this page was last updated on 6/16/2026.

Jennifer Bush Insider Trading History at Artiva Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/19/2026	Sell	8,790	$9.01	$79,197.90	337,920

Jennifer Bush Buying and Selling Activity at Artiva Biotherapeutics

Artiva Biotherapeutics Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Today's Range

Now: $9.73

$9.21

$10.00

50 Day Range

MA: $9.26

$6.80

$13.39

2 Week Range

Now: $9.73

$1.47

$14.53

Volume

215,878 shs

Average Volume

372,408 shs

Market Capitalization

$240.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4